UniQure, a gene-therapy company based in The Netherlands, has closed its initial public offering which raised $91.8m by selling 5.4 million shares of common stock.
UniQure has developed the first and currently only gene therapy product to receive approval in the European Union. The product, Glybera, was approved in October 2012 for the treatment of a subset of patients with lipoprotein lipase deficiency.
The initial public offering gives UniQure an initial market cap of approximately $286m. They trade on the Nasdaq under ticker symbol QURE. Jefferies and Leerink Partners served as lead underwriters and have a 30-day option to buy…
